Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Francisco Dieguez

Interventional Cardiology Hialeah, FL Medical Doctor

NPI 1013053859 CMS profile 317978

145 E 49Th St, Hialeah, FL 33013

Open in the dashboard

General payments

$59,875

515 records reported · program years 2019–2025

Research payments

$64,875

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$112,332 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Francisco Dieguez of Hialeah, FL is reported in the CMS Open Payments database as having received $59,875 across 515 general payments and $64,875 in research payments paid to them. Separately, studies naming them as principal investigator received $112,332 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Interventional Cardiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,904 41
2024 General $26,330 42
2023 General $19,492 67
2022 General $2,017 84
2021 General $3,508 110
2021 Research $64,875 3
2020 General $2,213 75
2019 General $4,411 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Francisco Dieguez
  • Interventional Cardiology median
  • Middle half of Interventional Cardiology
  • National median

In program year 2025, general payments to Francisco Dieguez were reported at $1,904. Among 6,173 Interventional Cardiology profiles paid that year, the median was $1,092 and the middle half received between $366 and $3,019.

Show as a table
Year Francisco Dieguez Interventional Cardiology median Middle half National median
2019 $4,411 $1,097 $329–$3,048 $163
2020 $2,213 $473 $161–$1,480 $114
2021 $3,508 $677 $233–$1,827 $132
2022 $2,017 $978 $333–$2,724 $149
2023 $19,492 $1,136 $382–$2,986 $160
2024 $26,330 $1,181 $395–$3,326 $164
2025 $1,904 $1,092 $366–$3,019 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AngioDynamics, Inc. $40,307 8 payments
  2. Ra Medical Systems, Inc. $2,696 46 payments
  3. Medtronic, Inc. $2,559 34 payments
  4. Bard Peripheral Vascular, Inc. $2,553 50 payments
  5. Abbott Laboratories $2,188 50 payments
  6. Biotronik Inc. $1,770 20 payments
  7. Boston Scientific Corporation $1,635 30 payments
  8. Janssen Pharmaceuticals, Inc $1,052 57 payments
  9. Pfizer Inc. $692 30 payments
  10. Merck Sharp & Dohme Corporation $461 25 payments
  11. Other $3,963 165 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $40,083 2 payments
  2. Food and Beverage $17,277 507 payments
  3. Debt forgiveness $1,605 1 payment
  4. Travel and Lodging $818 2 payments
  5. Education $92 3 payments
Products named General payments · program years 2019–2025
  1. Auryon Laser System 100-120 Vac $40,129 3 payments
  2. DABRA $2,030 24 payments
  3. XARELTO $1,052 57 payments
  4. CROSSER $618 12 payments
  5. VERQUVO $575 31 payments
  6. ELIQUIS $548 25 payments
  7. AVEIR $481 4 payments
  8. Resolute $469 15 payments
  9. LIFESTENT $419 5 payments
  10. Venclose Maven Catheter $389 10 payments
  11. Other $10,661 364 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Ra Medical Systems, Inc. $64,875 3 payments

Prescribing to Medicare patients

Part D · data year 2024 · 57 drugs

Part D claims

9,555

Median for Cardiology: 2,533

Drug cost

$1,080,248

Median for Cardiology: $485,213

Branded share of claims

43.9%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 503 $322,470
Eliquis Apixaban Brand 382 $245,431
Entresto Sacubitril/Valsartan Brand 280 $209,056
Brilinta Ticagrelor Brand 137 $69,831
Farxiga Dapagliflozin Propanediol Brand 96 $59,784
Repatha Sureclick Evolocumab Brand 54 $45,908
Ranolazine Er Ranolazine Brand 245 $20,738
Verquvo Vericiguat Brand 30 $19,416
Clopidogrel Clopidogrel Bisulfate Brand 1,772 $11,151
Multaq Dronedarone Hcl Brand 12 $9,661

The 10 drugs with the highest cost, of 57 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 64 billing codes

Paid by Medicare

$1,355,788

Of which drugs: $183

Medicare patients

384

Average age 79

Services billed

2,150

214 women, 170 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 68%
Depression 65%
Alzheimer's or dementia 65%
Diabetes 64%
Heart failure 46%
Chronic kidney disease 45%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, dipyridamole, per 10 mg J1245 Office 17 68 $178

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $114
$114 30 —
OPSUMIT
  • Actelion Pharmaceuticals US, Inc. $87
$87 — —
ELIQUIS
  • PFIZER INC. $63
  • E.R. Squibb & Sons, L.L.C. $23
$86 382 —
VYNDAMAX
  • PFIZER INC. $78
$78 — —
XARELTO
  • Janssen Pharmaceuticals, Inc $52
$52 503 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

518 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Cardiology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record